Gilead to develop second-generation protease inhibitor
January 15 2004 12:00 AM ET
Gilead Sciences filed an investigational new drug application Tuesday with the Food and Drug Administration to develop GS 9005, a once-daily protease inhibitor with a drug-resistance profile significantly different from those of existing protease inhibitors, The Wall Street Journal reports. Because of the drug's unique resistance profile, it could be effective for patients who've developed resistance to all other protease medications, company officials say. Gilead plans to begin early human tests later this year.
- WATCH: The 12 Gayest Holiday Spectaculars Ever!
- These Couples Prove Love Is Love
- Op-ed: What I Didn't Learn in Catholic School
- Salvation Army 'Does Not Consider Homosexual Orientation a Sin'
- Mass. Lt. Gov. Candidate Backs Marriage Equality; Conservatives Object
- 13 Classic Companies Top HRC's New Corporate Equality Index
- Media PHOTOS: Adam Lambert, Jane Lynch, Chris Colfer, Fergie at TrevorLIVE Benefit December 09 2013 9:41 PM
- Women New Family Ties: Meredith Baxter Marries Nancy Locke December 09 2013 8:01 PM
- Travel Spider-Man Will Welcome In 2014 In Times Square December 09 2013 7:52 PM
- Election Is Marriage Equality Still Politically Dangerous, Even in Mass.? December 09 2013 7:09 PM
- Entertainment News Tig Notaro Nominated for Best Comedy Album December 09 2013 6:08 PM
- HIV & AIDS Republican Pol: Gays Want Free Medical Care Because of AIDS December 09 2013 6:04 PM
- Parenting Israel Again Deals Gay Couples, Families Legislative Setback December 09 2013 4:10 PM